Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disease characterized by the loss of upper and lower motor neurons, leading to muscle weakness, paralysis, and typically death within 2-5 years of symptom onset. Despite decades of research and numerous clinical trials targeting neuroprotection, nearly all Phase II and III neuroprotective trials have failed to demonstrate efficacy. This knowledge gap explores the complex reasons behind this translational failure, examining historical trial data, preclinical-to-clinical translation challenges, species differences, trial design issues, and lessons from successful trials like tofersen.
| Trial Name |
Target |
Phase |
Year |
Outcome |
| idebenone |
Radical scavenger |
III |
2006 |
Failed primary endpoint |
| minocycline |
Anti-inflammatory |
III |
2007 |
Worse outcomes vs placebo |
| ceftriaxone |
Antibiotic/anti-glutamatergic |
III |
2013 |
Failed efficacy |
| talmavirsen |
Antisense |
II |
2014 |
Failed |
| Nuedexta |
Dextromethorphan/quinidine |
III |
2015 |
Failed |
| masitinib |
Tyrosine kinase inhibitor |
II/III |
2019 |
Mixed results, not FDA approved |
| edaravone |
Free radical scavenger |
III |
2017 |
Approved (conditional) |
| cirmtuzumab |
ROCK2 inhibitor |
II |
2023 |
Failed |
- Volume of failures: Over 50 clinical trials for ALS have failed since the 1990s
- Common targets: Most trials targeted glutamate excitotoxicity, oxidative stress, mitochondrial dysfunction, neuroinflammation, or protein aggregation
- Preclinical promise: Many compounds showed robust neuroprotection in animal models
- Translation gap: Success in SOD1 mouse models did not predict human efficacy
- Represents only ~2% of familial ALS cases
- Does not capture the more common sporadic ALS
- Rapid disease progression differs from human ALS
- Genetic background dramatically influences outcomes
- Overexpression models may not reflect endogenous protein dynamics
Pharmacokinetics:
- Rodents have different cytochrome P450 enzyme profiles
- blood-brain barrier permeability varies significantly between species
- Drug half-life differences affect dosing translation
- Protein binding differences affect free drug concentrations
Physiology:
- Motor neuron physiology differences between species
- Immune system differences affect neuroinflammatory responses
- Muscle mass differences affect drug distribution
- Dose translation errors: Human equivalent doses often miscalculated from animal studies
- Treatment timing: Animal studies often start treatment before symptom onset; humans start after diagnosis
- Duration mismatch: Short-term animal studies don't capture chronic treatment effects
- Outcome measure differences: Rotarod and grip strength don't translate to ALSFRS-R
| Parameter |
Mouse |
Human |
Implication |
| Lifespan |
2-3 years |
70-80 years |
Drug accumulation differs |
| Body surface area ratio |
0.006 m² |
1.8 m² |
Dose scaling factor ~12x |
| Liver metabolism |
Faster |
C slower |
Exposure differences |
| Brain capillary density |
Higher |
Lower |
BBB penetration varies |
- SOD1 models: Do not capture TDP-43 or FUS pathology seen in most ALS cases
- C9orf72 models: Phenotype less severe than human disease
- In vitro models: Lack systemic interactions and blood-brain barrier
- iPSC models: May not fully recapitulate adult-onset disease
- Subjective scoring with high variability
- Floor and ceiling effects
- Doesn't capture all functional domains equally
- Rate of progression varies significantly between patients
- Neurofilament light chain (NfL): Promising biomarker but not yet validated as primary endpoint
- Breathing function: Slow vital capacity has high variability
- Muscle strength: Difficult to measure reliably
- Biomarker composites: Not yet qualified by regulatory agencies
- C9orf72 (~40% familial, ~5-10% sporadic)
- SOD1 (~15-20% familial)
- FUS (~5% familial)
- ** TARDBP** (~5% familial)
- Unknown (~50-70% sporadic)
Different genetic subtypes may respond differently to treatments. Most trials have not stratified patients by genotype.
- Age of onset: 40-70 years range
- Site of onset: Bulbar vs limb vs respiratory
- Disease progression rate: Fast vs slow progressors
- Comorbidities: Varies significantly
- Concomitant medications: Polypharmacy effects unknown
¶ Dosing and Pharmacokinetic Issues
- Maximum tolerated dose approach: May not be optimal for neuroprotection
- Chronic dosing: Unknown long-term effects
- Drug interactions: Often not studied in ALS populations
- Biomarker-guided dosing: Not routinely implemented
- Diagnostic delay: Average 12-18 months from symptom onset to diagnosis
- Enrollment criteria: Often exclude slowly or rapidly progressing patients
- Geographic limitations: Access to trials limited
- Placebo response: Variable across populations
Tofersen (Qalsody) is an antisense oligonucleotide (ASO) targeting SOD1 mutations. It received FDA approval in 2023 for SOD1-ALS.
Success factors:
- Genetic targeting: Precisely targeted to patients with SOD1 mutations
- Biomarker-driven: Reduced SOD1 protein in CSF validated mechanism
- Disease modification signal: Slowed NfL decline in open-label extension
- Regulatory flexibility: Conditional approval based on biomarker endpoints
- Natural history integration: Used data from the GENESIS registry
- Genetic stratification is crucial for homogeneous populations
- Biomarker development should parallel clinical trials
- Conditional approval pathways can accelerate access
- Long-term extension studies are essential
- Genetic enrichment: Stratify by major genetic subtypes (C9orf72, SOD1, FUS, TARDBP)
- Biomarker integration: Use NfL for patient selection and endpoint qualification
- Adaptive designs: Allow mid-trial modifications based on interim data
- Platform trials: Test multiple compounds simultaneously with shared controls
- Master protocols: Standardize endpoints, assessments, and analytical approaches
- Earlier intervention: Target pre-symptomatic or very early symptomatic patients where possible
- Phenotypic stratification: Account for site of onset, progression rate
- Comorbidity screening: Exclude patients with confounding conditions
- International harmonization: Enable global enrollment
- PK/PD modeling: Use translational modeling to optimize human dosing
- Biomarker-guided dosing: Titrate based on target engagement markers
- Combination therapy: Consider multi-target approaches
- Composite endpoints: Combine functional and biomarker measures
- Digital health: Incorporate wearable sensors for continuous monitoring
- Patient-reported outcomes: Better capture quality of life
- Early FDA/EMA dialogue: Engage regulators before trial design
- Biomarker qualification: Invest in biomarker validation
- Accelerated approval: Utilize conditional approval pathways
The repeated failure of neuroprotective ALS trials stems from a complex interplay of factors: inadequate disease models, species translation challenges, trial design limitations, and patient heterogeneity. The success of tofersen demonstrates that precise genetic targeting, biomarker integration, and innovative trial design can overcome these barriers. Future ALS trials must embrace precision medicine approaches, integrate biomarkers throughout development, and adopt more sophisticated trial designs to finally translate promising preclinical findings into effective therapies.